Investment Thesis
Regeneron demonstrates exceptional financial health with industry-leading profitability metrics (31.4% net margin, 24.9% operating margin) and robust cash generation (4.1B FCF). The company maintains fortress-like balance sheet strength with minimal leverage (0.06x debt/equity) and exceptional liquidity (4.13x current ratio), providing strategic flexibility for R&D investments and shareholder returns.
REGN Strengths
- Exceptional profitability with 31.4% net margin significantly above pharma industry average
- Strong free cash flow generation of 4.1B representing 28.4% of revenue
- Fortress balance sheet with minimal debt (2.0B) and 3.1B cash position
- Superior liquidity metrics with 4.13x current ratio and 222.2x interest coverage
- Diluted EPS growth of 8.2% YoY outpacing revenue growth of 1.0%
REGN Risks
- Modest revenue growth of 1.0% YoY suggests potential product maturation or market challenges
- High insider trading activity (19 Form 4 filings in 90 days) warrants monitoring for potential concerns
- Absence of gross margin data limits visibility into cost structure and pricing power dynamics
- Pharmaceutical industry exposure to regulatory risk, patent expirations, and competitive pressures
Key Metrics to Watch
- Revenue growth acceleration trajectory in upcoming quarters
- Operating margin sustainability amid R&D investments
- Free cash flow consistency and capital allocation discipline
- New product pipeline progression and commercialization success
REGN Financial Metrics
Revenue
$14.3B
Net Income
$4.5B
EPS (Diluted)
$41.48
Free Cash Flow
$4.1B
Total Assets
$40.6B
Cash Position
$3.1B
REGN Profitability Ratios
Gross Margin
N/A
Operating Margin
24.9%
Net Margin
31.4%
ROE
14.4%
ROA
11.1%
FCF Margin
28.4%
REGN Balance Sheet & Liquidity
Current Ratio
4.13x
Quick Ratio
3.39x
Debt/Equity
0.06x
Debt/Assets
22.9%
Interest Coverage
222.23x
Long-term Debt
$2.0B
Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: Mar 18, 2026 |
Data as of: 2025-12-31 |
Powered by Claude AI